Cas:71653-06-0 3-Hydroxyaspartic Acid manufacturer & supplier

We serve Chemical Name:3-Hydroxyaspartic Acid CAS:71653-06-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-Hydroxyaspartic Acid

Chemical Name:3-Hydroxyaspartic Acid
CAS.NO:71653-06-0
Synonyms:3-hydroxyaspartic acid;EINECS 275-771-1
Molecular Formula:C4H7NO5
Molecular Weight:149.10200
HS Code:2922509090

Physical and Chemical Properties:
Melting point:287-288℃ (decomposition)
Boiling point:368.7ºC at 760 mmHg
Density:1.738g/cm3
Index of Refraction:1.583
PSA:120.85000
Exact Mass:149.03200
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-hydroxyaspartic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 275-771-1 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-hydroxyaspartic acid Use and application,3-hydroxyaspartic acid technical grade,usp/ep/jp grade.


Related News: One source familiar with the matter told Reuters that the J&J doses are expected to be exported to other countries. The doses are already in vials and ready for use, the other source said. 3-Hydroxyaspartic Acid manufacturer The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds. 3-Hydroxyaspartic Acid supplier Taiwan complained on Sunday that it was being punished because the World Health Organization considers it part of China, which has been subject to travel bans as the coronavirus spreads. 3-Hydroxyaspartic Acid vendor One source familiar with the matter told Reuters that the J&J doses are expected to be exported to other countries. The doses are already in vials and ready for use, the other source said. 3-Hydroxyaspartic Acid factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”